When Can We Expect A Profit From Spectral Medical Inc. (TSE:EDT)?

Spectral Medical Inc. (TSE:EDT) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The CA$347m market-cap company’s loss lessened since it announced a CA$48m loss in the full financial year, compared to the latest trailing-twelve-month loss of CA$36m, as it approaches breakeven. As path to profitability is the topic on Spectral Medical's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Expectations from some of the Canadian Biotechs analysts is that Spectral Medical is on the verge of breakeven. They expect the company to post a final loss in 2026, before turning a profit of CA$8.7m in 2027. Therefore, the company is expected to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 71% is expected, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

We're not going to go through company-specific developments for Spectral Medical given that this is a high-level summary, but, keep in mind that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Check out our latest analysis for Spectral Medical

Before we wrap up, there’s one issue worth mentioning. Spectral Medical currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

There are too many aspects of Spectral Medical to cover in one brief article, but the key fundamentals for the company can all be found in one place – Spectral Medical's company page on Simply Wall St. We've also put together a list of pertinent factors you should further research:

1. Historical Track Record: What has Spectral Medical's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Spectral Medical's board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.